Olezarsen sNDA
Severe Hypertriglyceridemia
NDA ReviewFDA Priority Review
Key Facts
Indication
Severe Hypertriglyceridemia
Phase
NDA Review
Status
FDA Priority Review
Company
About Ionis Pharmaceuticals
Founded in 1989 by Stanley T. Crooke, Ionis Pharmaceuticals is a pioneer in RNA therapeutics with over three decades of innovation in antisense oligonucleotide technology. The company has successfully transitioned to a fully integrated biotechnology organization, launching its first independent medicine TRYNGOLZA (olezarsen) for familial chylomicronemia syndrome. With six currently marketed medicines discovered and developed by Ionis, the company maintains a rich late-stage pipeline focused primarily on neurology and cardiology, while continuing to advance breakthrough RNA-targeted therapies that have redefined treatment for serious genetic diseases.
View full company profileTherapeutic Areas
Other Severe Hypertriglyceridemia Drugs
| Drug | Company | Phase |
|---|---|---|
| Plozasiran (ARO-APOC3) | Arrowhead Pharmaceuticals | Phase 3 |